VJ Harvey

2.3k total citations · 1 hit paper
16 papers, 954 citations indexed

About

VJ Harvey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, VJ Harvey has authored 16 papers receiving a total of 954 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in VJ Harvey's work include Testicular diseases and treatments (4 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer Treatment and Pharmacology (4 papers). VJ Harvey is often cited by papers focused on Testicular diseases and treatments (4 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer Treatment and Pharmacology (4 papers). VJ Harvey collaborates with scholars based in New Zealand, Australia and United Kingdom. VJ Harvey's co-authors include G Gill, Maureen Byrne, Val Gebski, Paul Thompson, Alan S. Coates, P. N. Jeal, Robert L. Woods, James F. Bishop, Martin H.N. Tattersall and Ray Snyder and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

VJ Harvey

16 papers receiving 902 citations

Hit Papers

Improving the Quality of Life during Chemotherapy for Adv... 1987 2026 2000 2013 1987 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer
    1987 419 citations Alan S. Coates, Val Gebski et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
VJ Harvey New Zealand 11 450 321 192 175 160 16 954
S. M. Crawford United Kingdom 20 612 1.4× 409 1.3× 354 1.8× 126 0.7× 240 1.5× 56 1.4k
G Gill Australia 8 445 1.0× 214 0.7× 64 0.3× 76 0.4× 181 1.1× 14 809
R. Dubbelman Netherlands 18 255 0.6× 201 0.6× 111 0.6× 302 1.7× 238 1.5× 35 981
Annette Wigertz Sweden 16 335 0.7× 166 0.5× 40 0.2× 197 1.1× 216 1.4× 19 1.0k
Tal Sella Israel 18 375 0.8× 142 0.4× 103 0.5× 128 0.7× 174 1.1× 66 1.0k
Jerzy E. Tyczynski United States 15 438 1.0× 197 0.6× 170 0.9× 213 1.2× 291 1.8× 38 1.1k
Enora Laas France 21 585 1.3× 181 0.6× 228 1.2× 211 1.2× 184 1.1× 97 1.5k
A. Bowman United Kingdom 16 354 0.8× 84 0.3× 72 0.4× 171 1.0× 182 1.1× 35 739
Douglas Adamson United Kingdom 16 276 0.6× 190 0.6× 170 0.9× 160 0.9× 123 0.8× 40 853
Lucìa Mangone Italy 22 1.3k 2.8× 289 0.9× 128 0.7× 345 2.0× 484 3.0× 96 2.1k

Countries citing papers authored by VJ Harvey

Since Specialization
Citations

This map shows the geographic impact of VJ Harvey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by VJ Harvey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites VJ Harvey more than expected).

Fields of papers citing papers by VJ Harvey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by VJ Harvey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by VJ Harvey. The network helps show where VJ Harvey may publish in the future.

Co-authorship network of co-authors of VJ Harvey

This figure shows the co-authorship network connecting the top 25 collaborators of VJ Harvey. A scholar is included among the top collaborators of VJ Harvey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with VJ Harvey. VJ Harvey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Ribi, Karin, Julie Aldridge, Kelly‐Anne Phillips, et al.. (2010). Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.. Journal of Clinical Oncology. 28(15_suppl). 527–527. 1 indexed citations
3.
Ribi, Karin, Kelly‐Anne Phillips, Zhe Sun, et al.. (2009). Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1–98 trial. Journal of Clinical Oncology. 27(15_suppl). 510–510. 5 indexed citations
4.
Harvey, VJ, Katrina Sharples, Randi Isaacs, et al.. (2008). A randomized phase II study comparing capecitabine (C) with C plus oral cyclophosphamide (CCy) in patients (pts) with advanced breast cancer (BC). Journal of Clinical Oncology. 26(15_suppl). 1077–1077. 1 indexed citations
5.
Toner, Guy C., Michael Boyer, Michael Jones, et al.. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet. 357(9258). 739–745. 75 indexed citations
6.
Harvey, VJ, et al.. (1996). Bilateral germ cell testicular tumors in New Zealand: experience in Auckland and Christchurch 1978-1994.. Journal of Clinical Oncology. 14(7). 2061–2065. 56 indexed citations
7.
Levi, J.A., Derek Raghavan, VJ Harvey, et al.. (1993). The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group.. Journal of Clinical Oncology. 11(7). 1300–1305. 102 indexed citations
8.
Thompson, Paul, et al.. (1988). Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance.. Journal of Clinical Oncology. 6(10). 1597–1603. 68 indexed citations
9.
Slevin, ML, et al.. (1988). Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule. British Journal of Cancer. 57(1). 115–116. 29 indexed citations
10.
Hardy, Janet, VJ Harvey, James W. Paxton, et al.. (1988). Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).. PubMed. 48(22). 6593–6. 23 indexed citations
11.
Coates, Alan S., Val Gebski, James F. Bishop, et al.. (1987). Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer. New England Journal of Medicine. 317(24). 1490–1495. 419 indexed citations breakdown →
12.
Osborne, Richard J., VJ Harvey, M L Slevin, J. H. Shepherd, & C J Williams. (1987). Phase II study of vinblastine and bleomycin in advanced ovarian cancer.. PubMed. 71(3). 335–6. 1 indexed citations
13.
Harvey, VJ, et al.. (1985). The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. British Journal of Cancer. 52(3). 363–367. 31 indexed citations
14.
Williams, C J, Graham M. Mead, Fergus Macbeth, et al.. (1985). Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.. Journal of Clinical Oncology. 3(11). 1455–1462. 87 indexed citations
15.
Harvey, VJ, et al.. (1984). The influence of cimetidine on the pharmacokinetics of 5‐fluorouracil.. British Journal of Clinical Pharmacology. 18(3). 421–430. 37 indexed citations
16.
Holdaway, I. M., et al.. (1980). Clinical applications of receptor measurements in breast cancer. British Journal of Cancer. 41(1). 136–139. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. M. Crawford Breakdown of academic impact, for papers by G Gill Breakdown of academic impact, for papers by R. Dubbelman Breakdown of academic impact, for papers by Annette Wigertz Breakdown of academic impact, for papers by Tal Sella Breakdown of academic impact, for papers by Jerzy E. Tyczynski Breakdown of academic impact, for papers by Enora Laas Breakdown of academic impact, for papers by A. Bowman Breakdown of academic impact, for papers by Douglas Adamson Breakdown of academic impact, for papers by Lucìa Mangone
Rankless by CCL
2026